Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037256 · ClinicalTrials.gov registry record · NA
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT02037256: Completed NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT02037256 is a NA study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02037256, a NA study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
Primary Outcome
Participants with \>= 2 fold increase in circulating PBSC's in blood and in apheresis collections in up to 4-days collection
Interventions
- PROCEDURE autologous hematopoietic stem cell transplantation
- BIOLOGICAL filgrastim
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-01-21 |
| Phase | NA |
What the finished NCT02037256 record still lists
NCT02037256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which autologous hematopoietic stem cell transplantation is the first listed.
NCT02037256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02037256 about?
NCT02037256 is a clinical study titled "Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma". This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
What is the current status of trial NCT02037256?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2011-07. Estimated completion is 2015-01-21.
What interventions are being tested in trial NCT02037256?
The interventions under investigation include: autologous hematopoietic stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), bortezomib (DRUG).
Who is sponsoring clinical trial NCT02037256?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02037256's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia